In collaboration with Merck, the intravenous formulation of Cardiome's lead molecule, vernakalant (IV), was granted marketing approval in September, 2010 in the European Union, Iceland and Norway under the trademark BRINAVESSTM for rapid conversion of recent onset AF to sinus rythm in adults. It continues to expand into new markets around the world. + READ MORE
21 November, 2013
Europace Publishes Data Supporting Use Of BRINAVESS™ (Vernakalant) As A First Line Agent For Pharmacological Cardioversion Of Atrial Fibrillation
18 November, 2013
Cardiome To Acquire Correvio LLC
Cardiome is a research-based biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the quality of life and health of patients. We strive to find innovative medicines that provide values to patients, physicians and healthcare systems.